Sepsis Diagnostics Market to Rise at a 8% CAGR through 2032 – Fact.MR Report

Sepsis Diagnostic Kits and Reagents to Bank US$ 300 Million in Revenue by 2031

The Fact.MR report on sepsis diagnostics market offers detailed analysis on the key growth drivers, restrains, and trends affecting demand in the market. The study also provides insights into the competitive landscape of global sepsis diagnostics market, identifying the key market players and analyzing the impact of their growth strategies.

Fact.MR – A Market Research and Competitive Intelligence Provider: Due to rising prevalence of sepsis and the growing burden of various infectious diseases, the global sepsis diagnostics market is showing consistent expansion. According to a Fact.MR analysis, the sepsis diagnostic market is anticipated to grow at an annual rate of 8% between 2021 and 2031.

The World Health Organization (WHO) estimates that approximately 30 million cases of sepsis are recorded each year. Furthermore, this disease affects around 1.2 million children and 3 million babies each year around the world. As a result, as the condition becomes more common, the demand for sepsis diagnostics will rise.

Similarly, the National Center for Biotechnology Information (NCBI) reports that the youngest and oldest age groups have the highest incidence. The need for sepsis diagnostics is projected to rise as a result of the multiple efforts being made by governments to eliminate this discrepancy and raise awareness about the condition.

For Critical Insights On This Market, Request For More Info

https://www.factmr.com/connectus/sample?flag=S&rep_id=391

Due to increased prevalence of sepsis and other infectious disorders, North America is expected to dominate the sepsis diagnostic market. The region’s main growth drivers have emerged as increased awareness and the advent of numerous technologically enhanced diagnostic methods.

Infection rates in developing nations are 3-20 times higher than in high-income countries, putting newborns at greater risk of HAI. Healthcare-associated infections account for 4 percent to 56 percent of all newborn deaths in underdeveloped countries, and 75 percent in Southeast Asia and Sub-Saharan Africa. According to these trends, the potential for sepsis detection technology and software will only grow.

“As the frequency of hospital admissions for various diseases increases, risk of developing sepsis during treatment is rising, prompting healthcare settings to incorporate sepsis diagnostics and detection systems, spurring heightened R&D to introduce new solutions”, comments a Fact.MR analyst.

Key Takeaways:

• By product, kits & reagents to be the most widely used sepsis diagnostic solutions.
• Automated sepsis diagnosis is gaining traction, aided by the introduction of significant technologies by leading vendors.
• By pathogen, gram positive bacterial sepsis diagnosis is gaining a lot of traction.
• By technology, microbiology testing is anticipated to outperform other approaches, with molecular diagnostics gaining traction.
• The Food and Drug Administration’s increasing approvals of crucial equipment are boosting sales possibilities in the United States.
• The United Kingdom is expected to have a high penetration rate as a result of increased government initiatives to reduce sepsis-related deaths.
• Technological advancements to broaden the market’s growth potential in Germany.
• The lack of institutional preparedness to deal with the influx of sepsis patients is driving the deployment of advanced equipment across India.

Growth Drivers

• The global sepsis diagnostic market will be driven by the rising occurrence of sepsis and other infectious disorders.
• The market will rise due to ongoing technical advancements in diagnostic systems.
• Increasing government awareness campaigns will increase demand for sepsis diagnostics.

Key Restraints

• The expansion of the sepsis diagnostic industry is being stifled by stringent regulatory government requirements for diagnostic approval.
• High diagnostic costs may stifle worldwide market expansion.
• The market’s expansion is being hampered by a scarcity of skilled professionals for advanced sepsis diagnostics.

To learn more about Sepsis Diagnostics Market, you can get in touch with our Analyst at

https://www.factmr.com/connectus/sample?flag=AE&rep_id=391

Competitive Landscape

The existence of a large number of diagnostic service providers peppers the worldwide sepsis diagnostics market, making it fiercely competitive. Among all the expansion techniques used, providing technologically enhanced solutions through extensive R&D remains the primary goal.

For instance,

• The VERIGENE® and VERIGENE® II Systems are especially intended to target infections in the respiratory systems, bloodstream and gastrointestinal tract, according to Luminex Corporation, a pioneer in diagnostics testing. These technologies make use of highly automated workflows to help with extraction, amplification, hybridization, and detection, all of which contribute to enhance clinical outcomes by preventing sepsis.
• Similarly, Abionic SA offers the abioSCOPE, a non-fluidic immunoassay technique that was tested on hundreds of patients in 14 European hospitals, with doctors verifying that sepsis identification was achievable more than 24 hours prior to conventional care in over 85 percent of the cases.

Key Companies Profiled by Fact.MR are –

• BioMerieux SA
• Becton Dickinson and Company (BD)
• Thermo Fisher Scientific Inc.
• Abbott Laboratories Inc.
• Roche Holdings AG
• T2 Biosystems Inc.
• Danaher Corporation (Beckman Coulter Inc.)
• Luminex Corporation
• Qiagen NV
• Siemens Healthineers
• Quidel Corporation
• Abionic SA
• OpGen Inc.
• Curetis NV

More Valuable Insights on Sepsis Diagnostics Market

Fact.MR, in its new report, offers an unbiased analysis of the global sepsis diagnostics market, analyzing forecast statistics through 2021 and beyond. The survey reveals growth projections on in sepsis diagnostics market with detailed segmentation:

• Product
  • Blood Culture Media
  • Instruments
  • Assays & Reagents
• Method
  • Conventional Sepsis Diagnostics
  • Automated Sepsis Diagnostics
• Pathogen
  • Gram-negative Bacterial Sepsis
  • Gram-positive Bacterial Sepsis
  • Fungal Sepsis
  • Other Pathogens
• Technology
  • Microbiology
  • Molecular Diagnostics
  • Immunoassays
  • Other Technologies
• Region
  • North America
  • Latin America
  • Europe
  • APEJ
  • Japan
  • Middle East & Africa

Explore Fact. MR’s Coverage on the Healthcare Domain

Predictive Diagnostics Market Insights - Predictive diagnostics is one strategy that healthcare organizations can use to improve outcomes while lowering costs. The use of predictive diagnostics is predicted to revolutionize the way the healthcare industry works, thanks to improvements in data-based technology and their convergence with healthcare practices.

Influenza A/B Combo Testing Market Forecast - The tremendous burden of a viral pandemic is driving the expansion of the global Influenza A/B combo testing market, resulting in a surge in demand for Influenza A/B combination testing. Influenza A/B combo testing accuracy, sensitivity, and advance diagnosis are always being improved by research and healthcare infrastructure.

Diabetes Diagnostics Market Insights - The global diabetes diagnostics market is growing at a rapid pace, owing to the rising prevalence of diabetes. Obesity is well-known as one of the major risk factors for diabetes. As a result of the rising prevalence of obesity, the diabetes diagnostics market will see increased growth.

Blood Transfusion Diagnostics Market Forecast - The recent COVID-19 epidemic has provided prospects for growth in the blood transfusion diagnostics market. Patients facing the disease are expected to benefit from this “convalescent plasma.” The global blood transfusion diagnostics market is expected to grow as a result of these factors.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com

Source: Fact.MR